Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance.
- NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_assertion description "[We hypothesized that bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), will potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of the head and neck (SCCHN).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance.
- NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_assertion evidence source_evidence_literature NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance.
- NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_assertion SIO_000772 21343546 NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance.
- NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_assertion wasDerivedFrom befree-20150227 NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance.
- NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_assertion wasGeneratedBy ECO_0000203 NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance.
- befree-20150227 importedOn "2015-02-27" NP772463.RAGd_gBVdpYdLQdsaKqY-No3efv6M5Mc6k8VktxKKGnpU130_provenance.